118 related articles for article (PubMed ID: 35670210)
1. Amelioration of glucose intolerance through directly acting antiviral agents in chronic hepatitis C cirrhotic patients without overt diabetes.
Jang TY; Lin YH; Liang PC; Yeh ML; Huang CI; Liu TW; Wei YJ; Hsu PY; Yang JF; Hou NJ; Wang CW; Hsieh MY; Lin ZY; Huang CF; Huang JF; Dai CY; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2022 Sep; 38(9):897-906. PubMed ID: 35670210
[TBL] [Abstract][Full Text] [Related]
2. Histopathology and the predominantly progressive, indeterminate and predominately regressive score in hepatitis C virus patients after direct-acting antivirals therapy.
Huang R; Rao HY; Yang M; Gao YH; Wang J; Jin Q; Ma DL; Wei L
World J Gastroenterol; 2021 Feb; 27(5):404-415. PubMed ID: 33584072
[TBL] [Abstract][Full Text] [Related]
3. Liver function following hepatitis C virus eradication by direct acting antivirals in patients with liver cirrhosis: data from the PITER cohort.
Quaranta MG; Ferrigno L; Tata X; D'Angelo F; Coppola C; Ciancio A; Bruno SR; Loi M; Giorgini A; Margotti M; Cossiga V; Brancaccio G; Dallio M; De Siena M; Cannizzaro M; Cavalletto L; Massari M; Mazzitelli M; De Leo P; Laccabue D; Baiocchi L; Kondili LA
BMC Infect Dis; 2021 May; 21(1):413. PubMed ID: 33947337
[TBL] [Abstract][Full Text] [Related]
4. Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1.
Salomone F; Catania M; Montineri A; Bertino G; Godos J; Rizzo L; Magrì G; Li Volti G
Liver Int; 2018 Jul; 38(7):1206-1211. PubMed ID: 29265719
[TBL] [Abstract][Full Text] [Related]
5. Over time evaluation of glycaemic control in direct-acting antiviral-treated hepatitis C virus/diabetic individuals with chronic hepatitis or with cirrhosis.
Cacciola I; Russo G; Filomia R; Pitrone C; Caccamo G; Giandalia A; Alibrandi A; Stella Franzè M; Porcari S; Maimone S; Saitta C; Squadrito G; Raimondo G
Liver Int; 2021 Sep; 41(9):2059-2067. PubMed ID: 33894103
[TBL] [Abstract][Full Text] [Related]
6. Real-world effectiveness of direct-acting antiviral agents for chronic hepatitis C patients with genotype-2 infection after completed treatment.
Cheng TS; Liang PC; Huang CF; Yeh ML; Huang CI; Lin ZY; Chen SC; Huang JF; Dai CY; Hsieh PH; Chuang WL; Yu ML
Kaohsiung J Med Sci; 2021 Apr; 37(4):334-345. PubMed ID: 33151016
[TBL] [Abstract][Full Text] [Related]
7. Factors associated with treatment failure of direct-acting antivirals for chronic hepatitis C: A real-world nationwide hepatitis C virus registry programme in Taiwan.
Chen CY; Huang CF; Cheng PN; Tseng KC; Lo CC; Kuo HT; Huang YH; Tai CM; Peng CY; Bair MJ; Chen CH; Yeh ML; Lin CL; Lin CY; Lee PL; Chong LW; Hung CH; Huang JF; Yang CC; Hu JT; Lin CW; Chen CT; Wang CC; Su WW; Hsieh TY; Lin CL; Tsai WL; Lee TH; Chen GY; Wang SJ; Chang CC; Mo LR; Yang SS; Wu WC; Huang CS; Hsiung CK; Kao CN; Tsai PC; Liu CH; Lee MH; Liu CJ; Dai CY; Kao JH; Chuang WL; Lin HC; Yu ML
Liver Int; 2021 Jun; 41(6):1265-1277. PubMed ID: 33655714
[TBL] [Abstract][Full Text] [Related]
8. High rate of sustained virological response with direct-acting antivirals in haemophiliacs with HCV infection: A multicenter study.
Mancuso ME; Linari S; Santagostino E; Bartolozzi D; D'Ambrosio R; Borghi M; Lampertico P; Peyvandi F; Castaman G; Aghemo A
Liver Int; 2020 May; 40(5):1062-1068. PubMed ID: 31876354
[TBL] [Abstract][Full Text] [Related]
9. Improvement of chronic HCV infection-related depression, anxiety, and neurocognitive performance in persons achieving SVR-12: A real-world cohort study.
Kaur H; Dhiman RK; Kulkarni AV; Premkumar M; Singh V; Duseja AK; Grover S; Grover GS; Roy A; Verma N; De A; Taneja S; Mehtani R; Mishra S; Kaur H
J Viral Hepat; 2022 May; 29(5):395-406. PubMed ID: 35266624
[TBL] [Abstract][Full Text] [Related]
10. Hepatitis C eradication improves cognitive function in patients with or without cirrhosis: A prospective real-life study.
Ibáñez-Samaniego L; Rapado-Castro M; Cabrero L; Navarrete C; García-Mulas S; Ahumada A; Marquez L; Pérez MD; Rincon D; Bañares R; Garcia-Martinez R
Eur J Neurol; 2022 Feb; 29(2):400-412. PubMed ID: 34634159
[TBL] [Abstract][Full Text] [Related]
11. The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Huang JF; Huang CF; Yeh ML; Dai CY; Hsieh MH; Yang JF; Huang CI; Lin YH; Liang PC; Lin ZY; Chen SC; Yu ML; Chuang WL
Kaohsiung J Med Sci; 2017 Nov; 33(11):567-571. PubMed ID: 29050674
[TBL] [Abstract][Full Text] [Related]
12. Sustained virological response: a milestone in the treatment of chronic hepatitis C.
Morisco F; Granata R; Stroffolini T; Guarino M; Donnarumma L; Gaeta L; Loperto I; Gentile I; Auriemma F; Caporaso N
World J Gastroenterol; 2013 May; 19(18):2793-8. PubMed ID: 23687416
[TBL] [Abstract][Full Text] [Related]
13. Improvement of hyperuricemia in chronic hepatitis C patients receiving directly acting antiviral agents.
Jang TY; Huang CI; Yeh ML; Liang PC; Tsai PC; Lin YH; Hsieh MY; Hou NJ; Lin ZY; Chen SC; Huang JF; Dai CY; Huang CF; Chuang WL; Yu ML
J Gastroenterol Hepatol; 2020 Mar; 35(3):473-481. PubMed ID: 31414504
[TBL] [Abstract][Full Text] [Related]
14. Virus Elimination by Direct-Acting Antiviral Agents Impacts Glucose Homeostasis in Chronic Hepatitis C Patients.
Cheng CH; Chu CY; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
Front Endocrinol (Lausanne); 2021; 12():799382. PubMed ID: 35095765
[TBL] [Abstract][Full Text] [Related]
15. HBV reactivation in patients with HCV/HBV cirrhosis on treatment with direct-acting antivirals.
Calvaruso V; Ferraro D; Licata A; Bavetta MG; Petta S; Bronte F; Colomba G; Craxì A; Di Marco V
J Viral Hepat; 2018 Jan; 25(1):72-79. PubMed ID: 28703895
[TBL] [Abstract][Full Text] [Related]
16. Treatment of Hepatitis C Cirrhotic Patients With Directly Acting Antivirals: A Multicenter Study.
Elfert AA; Abd-Elsalam S; Abo-Ali L; Eldemerdash T; Abou-Saif S; Elsabagh HM; Ebeid A; Badawi R
Infect Disord Drug Targets; 2021; 21(5):e270421186971. PubMed ID: 33076813
[TBL] [Abstract][Full Text] [Related]
17. Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients.
Cabibbo G; Celsa C; Calvaruso V; Petta S; Cacciola I; Cannavò MR; Madonia S; Rossi M; Magro B; Rini F; Distefano M; Larocca L; Prestileo T; Malizia G; Bertino G; Benanti F; Licata A; Scalisi I; Mazzola G; Di Rosolini MA; Alaimo G; Averna A; Cartabellotta F; Alessi N; Guastella S; Russello M; Scifo G; Squadrito G; Raimondo G; Trevisani F; Craxì A; Di Marco V; Cammà C;
J Hepatol; 2019 Aug; 71(2):265-273. PubMed ID: 30959157
[TBL] [Abstract][Full Text] [Related]
18. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study.
Giordanino C; Bugianesi E; Smedile A; Ciancio A; Abate ML; Olivero A; Pellicano R; Cassader M; Gambino R; Bo S; Ciccone G; Rizzetto M; Saracco G
Am J Gastroenterol; 2008 Oct; 103(10):2481-7. PubMed ID: 18702647
[TBL] [Abstract][Full Text] [Related]
19. Aminopyrine breath test predicts liver-related events and death in HCV-related cirrhosis on SVR after DAA therapy.
Petta S; Rini F; Calvaruso V; Cammà C; Ciminnisi S; Di Marco V; Giannini EG; Grimaudo S; Maria Pipitone R; Craxì A
Liver Int; 2020 Mar; 40(3):530-538. PubMed ID: 31507057
[TBL] [Abstract][Full Text] [Related]
20. Effects of direct-acting antiviral agents on lipid and glucose profile in HCV patients with type 2 diabetes: A real-life Italian experience.
Dalbeni A; Villani R; Bevilacqua M; Sacco F; Faccincani D; Cattazzo F; Cavallone F; Mantovani A; Ceruti V; Ieluzzi D; Paon V; Mantovani A; Serviddio G; Sacerdoti D
J Dig Dis; 2022 May; 23(5-6):324-330. PubMed ID: 35700113
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
